Baidu
map

Invest Ophthalmol Vis Sci.:通过实时成像的方法来研究人类干细胞诱导的视网膜类器官的的结构特征和功能

2017-07-04 cuiguizhong MedSci原创

美国南加州大学凯克大学眼科学系罗斯基眼科研究所的Cobrinik D教授团队近日在Invest Ophthalmol Vis Sci发表了他们的一项重要工作,他们利用实时成像的方法来研究人类干细胞诱导的视网膜类器官的的结构特征和功能。

美国南加州大学凯克大学眼科学系罗斯基眼科研究所的Cobrinik D教授团队近日在Invest Ophthalmol Vis Sci发表了他们的一项重要工作,他们利用实时成像的方法来研究人类干细胞诱导的视网膜类器官的的结构特征和功能。

利用人类多能干细胞(hPSC)诱导的视网膜类器官是研究视网膜发育、病理生理特征和细胞治疗的良好模型。传统的组织学分析是将不同时间固定的多个标本进行分析,来重建发育过程。与此相反,视网膜类器官通过相同生物组织的重复分析来研究其变化,是更直接的手段。在体外培养过程中,新的活体成像技术可以用来研究视网膜类器官结构和代谢功能。他们的工作是采用活体组织成像技术来研究视网膜类器官的发育,如随光感受器分化过程中的代谢变化。

Cobrinik D教授团队通过相差显微镜,光学相干断层扫描(OCT),荧光寿命成像显微镜(FLIM)和高光谱成像(HSpec)等技术手段,研究不同发育阶段的hPSC诱导的视网膜类器官的微观解剖组织和代谢功能的变化特征。并与通过组织学染色、免疫染色和固定类器官组织的微电脑层析(micro-CT)的研究结果相比较。

他们将类器官切成薄片,使用FLIM和HSpec技术手段来检测代谢活动的变化。FLIM检测结果发现,糖酵解活性逐渐增加;HSpec检测发现,视网膜类器官外层的视黄醇和视黄酸积聚,这与感光体起源的研究相吻合。micro-CT方法可以用来研究视网膜类器官的三维结构,但不能用来研究类器官的薄片样本。

因此,他们认为,实时成像技术可以在视网膜类器官中实现实时和非破坏性成像。FLIM和HSpec可以用来快速检测层状结构和光感受器的代谢。实时成像技术可以大大帮助人们在不同的实验和细胞治疗的条件下连续研究视网膜类器官的发育。  Cobrinik D教授团队的这项工作给人们研究视网膜的发育提供了更多的技术手段。

原文出处:

Browne, A.W., et al., Structural and Functional Characterization of Human Stem-Cell-Derived Retinal Organoids by Live Imaging. Invest Ophthalmol Vis Sci, 2017. 58(9): p. 3311-3318.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2050758, encodeId=b7082050e5824, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Oct 24 17:11:00 CST 2017, time=2017-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928950, encodeId=8c0f192895024, content=<a href='/topic/show?id=eae490e9620' target=_blank style='color:#2F92EE;'>#视网膜类器官#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90796, encryptionId=eae490e9620, topicName=视网膜类器官)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c8c241, createdName=w363522449, createdTime=Wed Jun 13 02:11:00 CST 2018, time=2018-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269901, encodeId=2244126990124, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Thu Jul 06 11:11:00 CST 2017, time=2017-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541227, encodeId=6f11154122e25, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Thu Jul 06 11:11:00 CST 2017, time=2017-07-06, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2050758, encodeId=b7082050e5824, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Oct 24 17:11:00 CST 2017, time=2017-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928950, encodeId=8c0f192895024, content=<a href='/topic/show?id=eae490e9620' target=_blank style='color:#2F92EE;'>#视网膜类器官#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90796, encryptionId=eae490e9620, topicName=视网膜类器官)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c8c241, createdName=w363522449, createdTime=Wed Jun 13 02:11:00 CST 2018, time=2018-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269901, encodeId=2244126990124, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Thu Jul 06 11:11:00 CST 2017, time=2017-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541227, encodeId=6f11154122e25, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Thu Jul 06 11:11:00 CST 2017, time=2017-07-06, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2050758, encodeId=b7082050e5824, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Oct 24 17:11:00 CST 2017, time=2017-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928950, encodeId=8c0f192895024, content=<a href='/topic/show?id=eae490e9620' target=_blank style='color:#2F92EE;'>#视网膜类器官#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90796, encryptionId=eae490e9620, topicName=视网膜类器官)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c8c241, createdName=w363522449, createdTime=Wed Jun 13 02:11:00 CST 2018, time=2018-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269901, encodeId=2244126990124, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Thu Jul 06 11:11:00 CST 2017, time=2017-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541227, encodeId=6f11154122e25, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Thu Jul 06 11:11:00 CST 2017, time=2017-07-06, status=1, ipAttribution=)]
    2017-07-06 zutt
  4. [GetPortalCommentsPageByObjectIdResponse(id=2050758, encodeId=b7082050e5824, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Oct 24 17:11:00 CST 2017, time=2017-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928950, encodeId=8c0f192895024, content=<a href='/topic/show?id=eae490e9620' target=_blank style='color:#2F92EE;'>#视网膜类器官#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90796, encryptionId=eae490e9620, topicName=视网膜类器官)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c8c241, createdName=w363522449, createdTime=Wed Jun 13 02:11:00 CST 2018, time=2018-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269901, encodeId=2244126990124, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Thu Jul 06 11:11:00 CST 2017, time=2017-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541227, encodeId=6f11154122e25, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Thu Jul 06 11:11:00 CST 2017, time=2017-07-06, status=1, ipAttribution=)]

相关资讯

Int Ophthalmol:早产儿眼睛屈光变化的长期评估:6年随访研究

土耳其Dokuz Eylul大学眼科学院的Yaman A教授团队近日在Int Ophthalmol发表了他们最近的一项工作,他们调查了有或无视网膜病变(ROP)的早产儿在出生后6年间的屈光不正随时间的变化。

Exp Eye Res:猪体内磷脂玻璃体液中的区域分布研究

美国路易斯维尔大学眼科与视觉科学系的Borchman D教授团队近日在Exp Eye Res杂志上发表了他们最新的一项工作,他们研究了猪体内磷脂玻璃体液中的区域分布情况。

Graefes Arch Clin Exp Ophthalmol:健康眼睛血管内视网膜异常

日本京都大学医学院眼科与视觉科学系的Tsujikawa A教授团队近日在Graefes Arch Clin Exp Ophthalmol杂志上发表了他们最新的一项研究,他们调查了健康眼睛中血管内视网膜异常的发生率和特征。

追老姚:他亲手为3万患者复明,数千眼科医生受益“姚氏法

1995年,33岁的姚玉峰登上了“世界之巅”,其独创的角膜移植术解决了排斥反应这个“世纪难题”,被国际眼科界命名为“姚氏法”,并被写入美国医学教科书。人的眼角膜厚度只有0.5毫米左右,却分作五层:上皮层、前弹力层、基质层、后弹力层、内皮层。1990年代,姚玉峰等一批科学家发现,造成穿透性角膜移植失败最主要的原因,是内皮层产生排斥反应。进而,姚玉峰揭开了角膜移植排斥反应的精细机理,设计出术后不发

Invest Ophthalmol Vis Sci:护骨素是增生性糖尿病视网膜病变在炎症和血管发生的新的调节因子

西班牙巴塞罗那巴尔的谢布伦研究所(CABERDEM)的Simó R的实验室团队近期在Invest Ophthalmol Vis Sci上发表了他们最近的一项工作,发现在增生性糖尿病视网膜病变中,护骨素对炎症和血管发生具有重要的作用。

眼科疾病手术护理常规

眼内手术一般护理常规

Baidu
map
Baidu
map
Baidu
map